Skip to main content
SpringerLink
Log in

Improved safety profile of newer fluoroquinolones

  • Chapter
  • First Online:
Fluoroquinolone Antibiotics

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Since their introduction to clinical use over half a century ago, antibiotics have become among the most commonly used drugs in a physician’s therapeutic armamentarium. There are, however, adverse effects that may be associated with these compounds and that range from mild, transient phenomena which may only be detectable by laboratory tests to severe life-threatening events such as anaphylaxis, seizures and on occasion ventricular arrhythmias. Fortunately these events are uncommon but it is incumbent upon physicians to be aware of them and to understand as much as possible about their pathogenesis. This paper reviews the general mechanisms of antibiotic toxicity, and focuses on the fluoroquinolone-related adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Braude, AI (1976) Harmful reactions, incompatibilities and interactions of antimicrobial drugs. In: LH Smith (ed.) Antimicrobial drug therapy vol. VIII. Saunders Co. Philadelphia, pp 100–147

    Google Scholar 

  2. Christensen LK, Skovsted L (1969) Inhibition of drug metabolism by chloramphenicol. Lancet 1397–1399

    Google Scholar 

  3. Sheldon WH, Heyman A (1949) Morphologic changes in syphilitic lesions during JarischHerxheimer reaction. Am J Syph Gonor Ven Dis 33: 213–224

    CAS  Google Scholar 

  4. Wemambu SN, Turk JL, Walters MF, Rees RJ (1969) Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet 2: 933–935

    Article  CAS  Google Scholar 

  5. Gootz TD, Brighty KE (1998) Chemistry and mechanism of action of the quinolone antibacteri-als. In: VT Andriole (ed.) The Quinolones, 2nd Edition. Academic Press, San Diego, pp 29–80

    Google Scholar 

  6. Hooper DC (2000) New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 30: 243–254

    Article  CAS  Google Scholar 

  7. Blum MD, Graham DJ, McCloskey CA (1994) Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 18: 946–950

    Article  CAS  Google Scholar 

  8. Ball P, Mandell L, Niki Y, Tillotson G (1999) Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 21(S): 407–421

    Article  CAS  Google Scholar 

  9. Domagala JM (1994) Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33: 685–706

    Article  CAS  Google Scholar 

  10. Zhanel GG, Walkty A, Vercaigne L, Karlowsky JA, Embil J, Gin AS, Hoban DJ (1999) The new fluoroquinolones: A critical review. Can J Infect Dis 10: 207–238

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Ball P, Tillotson G (1995) Tolerability of fluoroquinolone antibiotics: past, present and future. Drug Saf 13: 343–358

    Article  CAS  Google Scholar 

  12. Lipsky BA, Baker CA (1999) Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Inf Dis 28: 352–364

    Article  CAS  Google Scholar 

  13. Schmuck G, Schurmann A, Schluter G (1998) Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 42: 1831–1836

    Article  CAS  Google Scholar 

  14. Akahane K, Kimura Y, Tsutomi Y, Hayakawa I (1994) Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 38: 2323–2329

    Article  CAS  Google Scholar 

  15. Hon S, Shimada J, Saito A, Matsuda M, Miyailara T (1989) Comparison of the inhibitory effects of new quinolones on gamma-aminobutyric acid receptor binding in the presence of anti-inflammatory drugs. Rev Infect Dis 11 Suppl. 5: S1397–S1398

    Google Scholar 

  16. Janknegt R (1989) Drug interactions with quinolones. JAntimicrob Chemother 11: 33–43

    CAS  Google Scholar 

  17. Tokura Y (1998) Quinolone photoallergy: photosensitivity dermatitis induced by systemic administration of photohaptenic drugs. J Dermatol Sci 18: 1–10

    Article  CAS  Google Scholar 

  18. Robertson DG, Epling GA, Kiely JS, Bailey DL, Song B (1991) Mechanistic studies on the phototoxic potential of PD 117596, a quinolone antibacterial compound. Toxicology and Applied Pharmacology 1111:221–232

    Article  Google Scholar 

  19. Matsumoto M, Kajima K, Nagano H, Matsubara S, Yokota T (1992) Photostability and biological activity of fluoroquinolones substituted at the 8-position after UV irradiation. Antimicrob Agents and Chemother 36: 1715–1719

    Article  CAS  Google Scholar 

  20. Anon (1996) Grepafloxacin clinical investigators brochure. Greenford, UK: GlaxoWellcome research and development

    Google Scholar 

  21. Hayem G, Carbon C (1995) A reappraisal of quinolone tolerability: the experience of their musculoskeletal adverse effects. Drug Saf 13: 338–342

    Article  CAS  Google Scholar 

  22. Stahlmann R, Merker HJ, Hinz N, Chahoud I, Webb J, Heger W, Neubert D (1990) Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch Toxicol 64: 193–204

    Article  CAS  Google Scholar 

  23. Hynes RQ (1992) Integrins: Versatility, modulation and signaling in cell adhesion. Cell 69: 11–25

    Article  CAS  Google Scholar 

  24. Royer RJ, Pierfitte C, Netter P (1994) Features of tendon disorders with fluoroquinolones. Therapie 49: 75–76

    CAS  PubMed  Google Scholar 

  25. Paton JH, Reeves DS (1992) Adverse reactions to the fluoroquinolones. Adverse Drug Reaction Bulletin 153: 575–578

    Article  Google Scholar 

  26. FDA Talk paper (1999) FDA issues public health advisory on liver toxicity associated with the antibiotic Trovan. Rockville (MD): US Department of Health and Human Service, Food and Drug Administration 6 June

    Google Scholar 

  27. Press release, 15770/99, London: European Agency for the Evaluation of Medicinal Products. 20 May 1999

    Google Scholar 

  28. Lowe MN, Lamb, HM (2000) Gemifloxacin. Drugs 59(5): 1137–1148

    Article  CAS  Google Scholar 

  29. File TM, Schlemmer B, Garau J, Cupo M, Young C and the 049 Clinical Study Group (2001) Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin. JAC 48: 67–74

    Google Scholar 

  30. Ball. P, Wilson R, Mandell LA, Tremoliers F, Langan C, Henkel TJ and the Gemifloxacin 069 Study Group (2000) Effective short course therapy of acute exacerbation of chronic bronchitis (AECB) with once daily gemifloxacin. 3rd European Congress of Chemotherapy, Madrid, May 2000

    Google Scholar 

  31. Gehanno P, Poole MD, Wald ER, Weich-Jung C, Baran C, Henkel TJ and the Gemifloxacin 010 Study Group (2000) Efficacy of 7 days of gemifloxacin in patients with acute bacterial sinusitis (ABS). 3rd European Congress of Chemotherapy, Madrid, May 2000

    Google Scholar 

  32. Gruneberg RN, Schaeffer A, Goldstein F, Young C, and the gemifloxacin 014 study group (2000) Effective once daily gemifloxacin for the therapy of cmplicated UTI and pyelonephritis. 3rd European Congress of Chemotherapy, Madrid, May 2000

    Google Scholar 

  33. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M (1992) Liver damage from flucloxacillin, cloxacillin and dysloxacillin. J Hepatol 15: 154–161

    Article  CAS  Google Scholar 

  34. Garcia-Rodriguez L, Stricker BIH, Zimmerman HJ (1996) Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Inter Med 156: 1327–1332

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Disease, McMaster University, Henderson Hospital, 5th floor, 40 Wing, 711 Concession St, Hamilton, Ontario, L8V 1C3, Canada

    Lionel A. Mandell

Authors
  1. Lionel A. Mandell
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Medicine, The University of Manitoba, 409 Tacho Avenue, Winnipeg, Manitoba, R2H 2A6, Canada

    Allan R. Ronald

  2. Microbiology Laboratory, Mt. Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada

    Donald E. Low

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Basel AG

About this chapter

Cite this chapter

Mandell, L.A. (2003). Improved safety profile of newer fluoroquinolones. In: Ronald, A.R., Low, D.E. (eds) Fluoroquinolone Antibiotics. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8103-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8103-6_4

  • Published:

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9437-1

  • Online ISBN: 978-3-0348-8103-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation